Trials / Completed
CompletedNCT05367687
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
A Randomized, Open-Label, Multi-Center, Phase 2 Clinical Study of Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 251 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab、Rivoceranib | Camrelizumab: 200 mg, intravenous infusion. Rivoceranib: 250 mg, oral. |
| DRUG | Camrelizumab | Camrelizumab: 200 mg, intravenous infusion. |
Timeline
- Start date
- 2022-09-01
- Primary completion
- 2024-11-15
- Completion
- 2024-11-15
- First posted
- 2022-05-10
- Last updated
- 2025-11-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05367687. Inclusion in this directory is not an endorsement.